Gene therapy for adenosine deaminase deficiency

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 33-47

  Parkman, Robertson ^a   Weinberg, Kenneth ^a   Crooks, Gay ^a   Nolta, Jan ^a   Kapoor, Neena ^a   Kohn, Donald ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Gene expression; Gene therapy; Hematopoietic stem cell; Primary immunodeficiency; Retroviral vector

Indexed keywords

ADENOSINE DEAMINASE; FIBRONECTIN; VIRUS VECTOR;

BONE MARROW TRANSPLANTATION; ENZYME DEFICIENCY; GENE THERAPY; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; UMBILICAL CORD BLOOD;

ADENOSINE DEAMINASE; ANIMALS; BONE MARROW TRANSPLANTATION; CYCLIN-DEPENDENT KINASES; FETAL BLOOD; FIBRONECTINS; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE SYSTEM DISEASES; LENTIVIRUS; MICE; T-LYMPHOCYTES;

EID: 0034093243     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.33     Document Type: Review

References (51)

1. 1. Anderson WF. 1984. Prospects for human gene therapy. Science 226:401-9
2. 2. Nabel GJ, Gordon D, Bishop DK, et al. 1996. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA 93:15388-93
3. 3. Isner JM, Baumgartner I, Rauh G, et al. 1998. Treatment of thromboangiitis obliterans (Bueger's disease) by intramuscular gene transfer of vascular endothelial growth factor; preliminary clinical results. J Vasc. Surg. 28:965-73
4. 4. Chang MW, Barr E, Seltzer J, et al. 1995. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267:518-22
5. 5. Flotte T, Carter B, Conrad C, et al. 1996. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum. Gene Ther. 7:1145-59
6. 6. Wilson JM, Grossman M, Raper SE, et al. 1992. Ex vivo gene therapy of familial hypercholesterolemia. Hum. Gene Ther. 3:179-222
7. 7. Liu JM, Young NS, Walsh CE, et al. 1997. Retroviral mediated gene transfer of the Fanconi anemia complementation group C gene to hematopoietic progenitors of group C patients. Hum. Gene Ther. 8:1715-30
8. 8. Blaese RM, Culver KW, Miller AD, et al. 1995. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270:475-80
9. 9. Hoogerbrugge PM, van Beusechem VW, Fischer A, et al. 1996. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 3:179-83
10. 10. Bordignon C, Notarangelo LD, Nobili N, et al. 1995. Gene therapy in peripheral blood lymphocytes and bone marrow from ADA immunodeficient patients. Science 270:470-75
11. 11. Kohn DB, Weinberg K, Nolta J, et al. 1995. Engraftment of gene-modified cells from umbilical cord blood in neonates with adenosine deaminase deficiency. Nat. Med. 1:1017-23
12. 12. Parkman R, Gelfand EW, Rosen FS, et al. 1975. Severe combined immunodeficiency and adenosine deaminase deficiency. N. Engl. J. Med. 292:714-19
13. 13. Tjonnfjord GE, Steen R, Veiby OP, et al. 1994. Evidence for engraftment of donor-type multipotent CD34+ cells in a patient with selective T-lymphocyte reconstitution after bone marrow transplantation for B-SCID. Blood 84:3584-89
14. 14. Hirschhorn R, Yang DR, Puck JM, et al. 1996. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat. Genet. 13:290-295
15. 15. Hershfield MS. 1998. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Sem. Hematol. 35:291-98
16. 16. Meuwissen HJ, Pollara B, Pickering RJ. 1975. Combined immunodeficiency disease associated with adenosine deaminase deficiency. J. Pediatr. 86:169-81
17. 17. Lim B, Williams DA, Orkin SH. 1987. Retrovirus-mediated gene transfer of human adenosine deaminase expression of functional enzyme in murine hematopoietic stem cells in vivo. Mol. Cell Biol. 7:3459-65
18. 18. Ferrari G, Rossini S, Giavazzi R, et al. 1991. An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science 251:1363-66
19. 19. Kohn DB, Hershfield MS, Carbonaro D, et al. 1998. Selective accumulation of T lymphocytes containing a normal ADA gene four years after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat. Med. 4:775-780
20. 20. Pollok KE, Hanenerg H, Noblitt TW, et al. 1998. High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J. Virol. 72:4882-92
21. 21. Bowtell DDL, Cory S, Johnson GR, et al. 1988. Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes. J. Virol. 62:2464-73
22. 22. Flanagan JR, Krieg AM, Max EE, et al. 1989. Negative control region at the 5′ end of murine leukemia virus long terminal repeat. Mol. Cell Biol. 9:739-46
23. 23. Colicelli J, Goff SP. 1987. Isolation of a recombinant murine leukemia virus utilizing a new primer tRNA. J. Virol. 57:37-45
24. 24. Challita P-M, Kohn DB. 1994. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells in associated with methylation in vivo. Proc. Natl. Acad. Sci. USA 91:2567-71
25. 25. Challita P-M, Skelton D, El-Khoueiry A, et al. 1995. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J. Virol. 69:748-55
26. 26. Hawley RG, Lieu FH, Fong AZ, et al. 1994. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1:136-38
27. 27. Robbins RB, Xiao-Jin Y, Skelton DM, et al. 1997. Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J. Virol. 71:9466-74
28. 28. Halene S, Robbins PB, Cooper RM, et al. 1998. Long-term expression of eGFP in high percentage of murine hematopoietic cells by modified retroviral vector. Am. Soc. Gene Ther. 103a (Abstr.)
29. 29. Dunbar CE, Kohn DB, Schiffman R, et al. 1998. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease; in vivo detection of transduced cells without myeloablation. Hum. Gene Ther. 9:2629-40
30. 30. Hao QL, Shah AJ, Thiemann FT, et al. 1995. A functional comparison of CD34+ CD38- cells in cord blood and bone marrow. Blood 86:3745-53
31. 31. Nolta JA, Smogorzewska EM, Kohn DB. 1994. Analysis of optimal conditions for retroviral-mediated transduction of primitive human hematopoietic stem cells. Blood 86:101-10
32. 32. Nolta JA, Dao MA, Wells S, et al. 1996. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice. Proc. Natl. Acad. Sci. USA 93:2414-19
33. 33. Dao MA, Hannum CH, Kohn DB, et al. 1997. FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction. Blood 89:446-56
34. 34. Williams DA, Rios M, Stephens C, et al. 1991. Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature 352:438-41
35. 35. Moritz T, Dutt P, Xiao X, et al. 1996. Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood 88:855-62
36. 36. Moritz T, Patel VP, Williams DA. 1994. Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors. J Clin. Invest. 93:1451-57
37. 37. Dao MA, Hashino K, Kato I, et al. 1998. Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem and progenitor cells. Blood 92:4612-21
38. 38. Weinberg RA. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-30
39. kip-1 coupled with transforming growth factor β neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells. Proc. Natl. Acad. Sci. USA 95:13006-11
40. 40. Naldini L, Blömer U, Gallay P, et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-67
41. 41. Gallay P, Swingler S, Song J. 1995. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell 83:569-79
42. 42. Sutton RE, Wu HTM, Rigg R, et al. 1998. Human immunodeficiency virus Type 1 vectors efficiently transduce human hematopoietic stem cells. J. Virol. 72:5781-88
43. 43. Uchida N, Sutton RE, Friera AM, et al. 1998. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 95:11939-44
44. 44. Miyoshi H, Smith KA, Mosier DE, et al. 1999. Efficient transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283:682-86
45. 45. Case SS, Price MA, Jordan CT, et al. 1999. Stable transduction of quiescent CD34+, CD38-human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl. Acad. Sci. USA 96:2988-93
46. 46. Mastromarino P, Conti C, Goldoni P, et al. 1987. Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J. Gen. Virol. 9:2359-69
47. 47. Weinberg KI, Kohn DB. 1998. Gene therapy for congenital lymphoid immunodeficiency diseases. Sem. Hematol. 35:354-66
48. 48. Noguchi M, Yi H, Rosenblatt HM, et al. 1993. Interleukin 2 receptor γ chain mutations results in X-linked severe combined immunodeficiency in humans. Cell 73:147-57
49. 49. Nolta JA, Arakawa-Hoyt HJ, Dao M, et al. 1998. Development of IL-2 responsive human T lymphocytes in BNX mice after transplantation of CD34+ progenitors from X-SCID patients transduced with a normal γc gene. Am. Soc. Gene Ther. 1:109a (Abstr.)
50. 50. Bunting KD, Sangster MY, Ihle JN, et al. 1998. Restoration of lymphocyte function in Janus Kinase 3-deficient mice by retroviral-mediated gene transfer. Nat. Med. 4:58-64
51. 51. Brown MP, Topham DJ, Sangster, et al. 1998. Thymic lymphoproliferative disease after successful correction of CD34 ligand deficiency by gene transfer in mice. Nat. Med. 4:1253-60